Recombinant coagulation factor VIII(Chia Tai-Tianqing) NCT06297655…

Explore the PatSnap Life Sciences MCP marketplace

This Clinical Landscape Report was built with PatSnap Life Sciences MCP workflows. Clinical Trials MCP supplies protocol and result records, Drug & Asset MCP adds asset context, and Company & Deal Intelligence MCP resolves sponsor background. Use the same structured MCP building blocks in your research workflow.

Data snapshot: 18 September 2026. This strategic research report is not medical, regulatory or investment advice. Trial status and dates can change.

Phase 3

Clinical phase

Active, not recruiting

Recruitment status

60

Planned enrollment

2026-07-01

Primary-completion proxy

Executive view

NCT06297655 evaluates Recombinant coagulation factor VIII(Chia Tai-Tianqing) in Hemophilia A. The disclosed sponsor is Chia Tai Tianqing Pharmaceutical Group Co., Ltd., the design is Interventional, and the geographic footprint is China. The first listed primary endpoint is The proportion of on-demand treatment improvement for newly occurring bleeding events, assessed over For each new bleeding event, assessed within 72 hours after initial treatment.

The key landscape question is whether this protocol can generate a clinically interpretable signal relative to nearby programs. Phase alone is not a measure of evidence quality. Endpoint relevance, comparator choice, masking, enrollment feasibility, patient selection, country coverage and follow-up must be considered together.

PatSnap MCP Servers make this assessment reproducible by keeping protocol facts, result evidence, asset attributes and sponsor identity in separate structured calls.

How the MCP evidence stack was assembled

Clinical Trials MCP clinical_trial_fetch retrieved the design, outcomes, phase, status, enrollment, sponsor, countries and timing for NCT06297655 and selected peers. clinical_trial_result_fetch supplied detailed result records from the wider Hemophilia A landscape. Drug & Asset MCP drug_fetch was queried for Recombinant coagulation factor VIII(Chia Tai-Tianqing), while Company & Deal Intelligence MCP organization_fetch was queried for Chia Tai Tianqing Pharmaceutical Group Co., Ltd..

This separation reduces a common diligence error: treating a registry label, a company description or a result excerpt as if each represented the complete evidence package. Explore the source workflow at the PatSnap MCP marketplace.

Trial landscape table

Trial	Asset / intervention	Phase / status	Sponsor	Geography	Primary endpoint	Readout proxy
NCT06297655	Recombinant coagulation factor VIII(Chia Tai-Tianqing)	Phase 3 / Active, not recruiting	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	China	The proportion of on-demand treatment improvement for newly occurring bleeding events For each new bleeding event, assessed within 72 hours after initial t…	2026-07-01
NCT06864975	Recombinant Human Coagulation Factor VIII (Takeda)	Phase 4 / Recruiting	Beijing Children's Hospital.Captital Medical University	China	Success within 24 months	2028-03-01
CTRI/2025/03/081608	Freeze-dried Concentrated Human Blood Coagulation Factor IX(Japan Blood Products Organization)	Phase 4 / Not Yet Recruiting	Reliance Life Sciences Pvt Ltd.	India		Timing not reported
NCT06833983	GS1191-0445	Phase 3 / Recruiting	Gritgen Therapeutics Co., Ltd	China	Annualized Bleeding Rate (ABR) Weeks 3 to 52 after infusion	2026-11-30
NCT06752850	Efanesoctocog alfa	Phase 4 / Active, not recruiting	Swedish Orphan Biovitrum AB	Sweden, Norway, Italy, Spain	Haemophilia Early Arthropathy Detection with Ultrasound (HEAD-US) synovial hypertrophy domain score decrease. Baseline to 12 months	2026-11-17

The table aligns endpoints, sponsors, phases, geographies and readout proxies. It is descriptive, not a head-to-head efficacy comparison. Differences in population, baseline risk, intervention schedule and follow-up can dominate apparent cross-trial differences.

Reproduce the trial-to-asset workflow with PatSnap MCP

Protocol design and endpoint interpretation

NCT06297655 is a Phase 3, active, not recruiting study with 60 planned participants. Allocation is N/A, masking is None (Open Label), and the intervention model is Single Group Assignment.

The primary endpoint is “The proportion of on-demand treatment improvement for newly occurring bleeding events” over “For each new bleeding event, assessed within 72 hours after initial treatment.” The retrieved endpoint description is: Evaluate the hemostatic efficacy of the patient after each new bleeding event (including new bleeding events during visits and new bleeding events during home treatment), and calculate the proportion of improvement as excellent+good to the total number of on-demand treatment evaluations..

Interpretation should test whether the endpoint captures a clinically meaningful change, whether its time horizon matches the proposed biology, and whether treatment discontinuation or missing data can bias the estimate. The planned enrollment of 60 should be assessed against expected effect size, event frequency, multiplicity, subgroup plans and attrition.

No named control drug was returned in the protocol field set. A placebo comparator can strengthen internal efficacy assessment, while an active comparator may better test clinical differentiation. Single-arm and open-label programs require greater weight on objective outcomes, independent assessment and external benchmarks.

Indexed readouts in the surrounding landscape

5 recent result records were selected as contextual evidence for Hemophilia A. These records do not establish direct evidence for NCT06297655 unless the registration number matches.

A Phase 3 Study of the Safety and Efficacy of Coagulation Factor VIIa (Recombinant) for the Prevention of Excessive Bleeding in Patients With Congenital Hemophilia A or B With Inh…

Phase 3; n=2; No numerical result field reported Source: https://clinicaltrials.gov/ct2/show/results/NCT05695391

ISTH 2026 （Mim8）3 A FRONTIER ，

3; n=426; AE(Injection-site reactions (ISRs)) = 2.0 % ; AE(Injection-site reactions (ISRs)) = 1.8 % Source: https://www.novonordisk.com.cn/content/nncorp/cn/zh_cn/news---media/2026071401.html

UPFRONT CYDRI IS MORE EFFECTIVE FOR THE TREATMENT OF ACQUIRED HEMOPHILIA A THAN TRADITIONAL ORAL IMMUNOSUPPRESSION

Not Applicable; n=202; OS(2-year) = 68.9 % ; OS(2-year) = 93.2 % Source: https://library.ehaweb.org/eha/2026/eha-2026/4206874/imre.bod.upfront.cydri.is.more.effective.for.the.treatment.of.acquired.html

Result fields should be reconciled with the source record before quantitative comparison. Population definitions, analysis sets, dose cohorts, estimands, confidence intervals, rescue therapy and follow-up can materially change the meaning of a numerical endpoint. Clinical Trials MCP supports repeatable refreshes as result records change.

Asset and sponsor context

Recombinant coagulation factor VIII(Chia Tai-Tianqing) is indexed as Recombinant coagulation factor with F10 biology and a global stage of Approved. The asset profile lists Chia Tai Tianqing Pharmaceutical Group Co., Ltd. as an originator or developer.

Chia Tai Tianqing Pharmaceutical Group Co., Ltd. is indexed in China with the website http://www.cttq.com. Manufactures pharmaceutical products The record lists 146 development-stage drug assets.

For execution diligence, monitor sponsor ownership, collaborator additions, site expansion, protocol amendments and enrollment revisions. A change in ownership or geography can alter operational confidence as well as the commercial meaning of a future readout.

Development white space

Endpoint white space. Determine whether a more patient-relevant outcome, longer durability window or blinded central assessment would resolve uncertainty left by the current endpoint.
Population white space. Test biomarker-defined, treatment-line or risk-stratified subgroups where effect size and unmet need could be clearer.
Comparator white space. Identify whether the study can support differentiation against the current standard of care rather than only activity against baseline or placebo.
Geographic white space. Assess whether the disclosed footprint supports recruitment, regulatory transferability and commercial generalizability.
Sequencing white space. Clarify whether Recombinant coagulation factor VIII(Chia Tai-Tianqing) is intended for monotherapy, combination, maintenance, rescue or an earlier treatment line.

White space should be framed as an unanswered development question, not merely an unoccupied mechanism label. A credible program closes a measurable clinical uncertainty with a design that can be executed and interpreted.

Strategic implications and next readouts

For sponsors, the endpoint hierarchy, safety window, enrollment pace and protocol amendment history should all support the same target product profile. Advancement criteria should be set before the readout and tied to clinical effect, uncertainty, tolerability and operational feasibility.

For business-development teams, differentiation may come from a sharper population, stronger comparator, more durable benefit, simpler delivery or clearer sequencing role. For investors, the central risk is evidence quality relative to time and capital, not the phase label in isolation.

Track recruitment status, enrollment changes, primary-completion timing, endpoint revisions, new result records, sponsor ownership and collaborator changes. Re-run the PatSnap MCP workflow when a surrogate becomes a clinical outcome, a single-country study expands, the comparator changes or a new result materially shifts the competitive benchmark.

Source trail and bottom line

Anchor trial: NCT06297655
Protocol source: https://clinicaltrials.gov/study/NCT06297655
MCP sources: Clinical Trials MCP (clinical_trial_fetch and clinical_trial_result_fetch); Drug & Asset MCP (drug_fetch); Company & Deal Intelligence MCP (organization_fetch).
Data snapshot: 18 September 2026.

Recombinant coagulation factor VIII(Chia Tai-Tianqing) in Hemophilia A is best understood through the interaction of protocol design, surrounding readouts, asset context and sponsor execution. The current record makes The proportion of on-demand treatment improvement for newly occurring bleeding events and 2026-07-01 the leading decision points.

Build and refresh clinical landscape reports with PatSnap MCP